Jun 4, 2021

ImaginAb完成1280万美元融资以加速增长计划 本文共1385个字，阅读需4分钟 Latest financing will advance the clinical development of its CD8 ImmunoPET agent and build on its market leading position.LOS ANGELES, June 3, 2021 /PRNewswire/ -- ImaginAb Inc, a leading biotechnology company focused on developing next generation radiopharmaceutical imaging and therapy agents, has secured an additional $12.8 million in growth capital.The financing was led by existing investors Adage Capital and Cycad Group and includes new investors Norgine Ventures and Theravance Respiratory Company. Current investor Jim Pallotta of the Raptor Group also participated in the financing. "ImaginAb's vision is to be the lead in diagnostic and treatment choices, helping patients live better and healthier lives," noted Ian Wilson, ImaginAb's CEO. "This latest round of financing will ensure that we have the financial strength to continue our growth trajectory including further recruitment and expansion of our ongoing CD8 ImmunoPET clinical trials being administered in over 20 hospitals in North America, Europe and Australia, and Increased R&D activities leveraging platform technology to develop 'best in class' therapeutic radiopharmaceuticals (RPT)."K. Leonard Judson, Chairman of ImaginAb commented,"We are pleased to secure this financing to support our imaging and RPT initiatives. ImaginAb is an innovative leader within the ImmunoPET imaging field and have experienced strong revenue growth over the last 12 months as our technology continues to be embraced by our pharma and biotech partners. "Judson continued "We are excited about our ongoing Phase II trial, and the potential insights our agent offers into the patient's health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs".About ImaginAbImaginAb Inc. is a biotechnology company focused on developing radiopharmaceutical imaging and therapy agents. ImaginAb engineer antibody fragments called Minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET Imaging technology and therapeutic isotopes, these novel Minibodies bind specifically to cell surface targets, providing physicians with a whole-body picture of immune activity and the potential to treat cancer.ImaginAb is advancing a pipeline of Minibodies against both oncology and immunology targets. The Company is backed by top tier venture capital firms and strategic corporate firms including, Adage Capital, The Cycad Group, Norgine Ventures, TRC, Jim Pallotta of the Raptor Group, The Parker Institute for Cancer Immunotherapy, and Merck (MSD) Pharma.About CD8 ImmunoPETThe 89Zr CD8 Immuno-PET agent ([89Zr]-Df-IAB22M2C) is a [89Zr]-labelled minibody that binds the CD8 receptor on human T cells and is used for quantitative, non-invasive PET imaging of CD8 T cells in patients. CD8 T cells are the main effector cells involved in the immune response against tumor cells induced by immunotherapies and they also play a key role in multiple autoimmune diseases. As such, quantitative imaging of CD8 T cells can be used to diagnose the immune status of a patient, to measure the efficacy of immunotherapies and predict patient outcomes.For further information please contact:ImaginAbIan WilsonCEOEmail: info@imaginab.comPhone: +1 310 645 1211 View original content to download multimedia:http://www.prnewswire.com/news-releases/imaginab-completes-12-8-million-financing-to-accelerate-growth-plans-301305407.htmlSOURCE ImaginAb, Inc. 最新融资将推动其CD8免疫疗法的临床开发，并巩固其市场领先地位。洛杉矶2021年6月3日电/PRNewswire/--专注于开发下一代放射性药物成像和治疗剂的领先生物技术公司ImaginAb Inc.获得了1280万美元的额外增长资本。融资由现有投资者Adage Capital和Cycad Group牵头，包括新的投资者Norgine Ventures和Theravance Respiratory Company。猛禽集团的现任投资人吉姆·帕洛塔也参与了融资。Imaginab公司的首席执行官伊恩·威尔逊说：“Imaginab公司的愿景是成为诊断和治疗选择的领先者，帮助病人过上更好和更健康的生活。“最新一轮融资将确保我们有资金实力继续我们的增长轨迹，包括进一步招募和扩大我们正在北美、欧洲和澳大利亚的20多家医院进行的CD8免疫疗法临床试验，以及利用平台技术增加研发活动，开发‘一流’治疗性放射性药物(RPT)。”ImaginAb董事长K.Leonard Judson评论说，“我们很高兴获得这笔资金，以支持我们的成像和RPT计划。ImaginAb公司是ImmunoPET成像领域的创新领导者，在过去12个月中，随着我们的技术继续得到我们的制药和生物技术合作伙伴的支持，公司的收入实现了强劲增长。”贾德森继续说：“我们对我们正在进行的II期试验感到兴奋，我们的代理人为患者健康提供了潜在的见解--使免疫肿瘤疗法和其他药物的患者选择和治疗监测更好。”关于ImaginAbImaginAb公司是一家专注于开发放射性药物成像和治疗剂的生物技术公司。ImaginAb工程的抗体片段称为微型体，保持全长抗体的精致特异性，同时在体内保持生物惰性。与广泛可用的PET成像技术和治疗同位素一起使用，这些新型微体特异性地结合细胞表面靶点，为医生提供免疫活动的全身图像和治疗癌症的潜力。ImaginAb正在推进一条针对肿瘤和免疫学靶标的微体管道。该公司得到顶级风险投资公司和战略公司的支持，其中包括Adage capital、Cycad Group、Norgine Ventures、TRC、Raptor Group的Jim Pallotta、帕克癌症免疫疗法研究所和默克制药公司。关于CD8免疫组化89Zr CD8免疫-PET试剂([89Zr]-DF-IAB22M2C)是一种[89Zr]标记的微体，其结合人T细胞上的CD8受体，用于患者CD8 T细胞的定量、非侵入性PET成像。CD8 T细胞是参与免疫治疗诱导的肿瘤细胞免疫应答的主要效应细胞，在多种自身免疫性疾病中起着关键作用。因此，CD8 T细胞的定量成像可用于诊断患者的免疫状态、测量免疫治疗的疗效和预测患者的结果。如需更多信息，请联系：Imaginab伊恩·威尔逊首席执行官电子邮件:info@imaginab.com电话:+1 310 645 121 1查看原创内容下载多媒体：http://www.prnewswire.com/news-releases/imaginab-completes-12-8-million-financing-to-accelerate-growth-plans-301305407.html资料来源：ImaginAb,Inc. 以上中文文本为机器翻译，存在不同程度偏差和错误；偶尔因源网页结构局限，内容无法一次完整呈现。请理解并参考原站原文阅读。